CC logo

Chemours Company (The) (CC)

$15.85

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CC

Market cap

$2.39B

EPS

-2

P/E ratio

--

Price to sales

0.41

Dividend yield

2.208%

Beta

1.436105

Price on CC

Previous close

$15.26

Today's open

$15.51

Day's range

$15.44 - $16.03

52 week range

$10.44 - $28.67

Profile about CC

CEO

Denise M. Dignam

Employees

5700

Headquarters

Wilmington, DE

Exchange

New York Stock Exchange

Shares outstanding

150498995

Issue type

Common Stock

CC industries and sectors

Materials

Chemicals

News on CC

Chemours Expands Low-GWP Refrigerant Portfolio for Data Centers

CC expands its low-GWP Opteon refrigerant portfolio to meet rising cooling needs from AI-driven data centers and support decarbonization goals.

news source

Zacks Investment Research • Aug 14, 2026

news preview

The Chemours Company (CC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN THE CHEMOURS COMPANY (CC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by emai.

news source

Business Wire • Aug 13, 2026

news preview

Securities Fraud Investigation Into The Chemours Company (CC) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CHEMOURS COMPANY (CC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On Augus.

news source

Business Wire • Aug 13, 2026

news preview

Chemours' Q2 Earnings & Revenues Lag Estimates on Lower Volumes

CC's Q2 loss narrows, but lower volumes and sales weigh on results as it outlines a cautious Q3 outlook.

news source

Zacks Investment Research • Aug 11, 2026

news preview

Chemours Launches Opteon™ ZE and Opteon™ 515B Refrigerants for Chiller Applications Powering Data Centers, Commercial Buildings, and Other Mission Critical Environments

New additions to the Opteon™ portfolio support high-performance, sustainable cooling solutions in stationary chillers for AI-driven data centers, and commercial HVAC applications WILMINGTON, Del., Aug. 10, 2026 /PRNewswire/ -- The Chemours Company (Chemours) (NYSE: CC), a global chemistry company, today announced the launch of Opteon™ ZE (R-1234ze(E)) and Opteon™ 515B (R-515B) for stationary chiller applications.

news source

PRNewsWire • Aug 10, 2026

news preview

New Jersey's $2.5 billion 'forever chemicals' settlements with DuPont, 3M, others win court approval

A federal judge on Friday approved more than $2.5 billion of ‌settlements that New Jersey reached with DuPont , Chemours , Corteva and 3M to resolve claims over pollution attributed to PFAS, also known as “forever chemicals.”

news source

Reuters • Aug 7, 2026

news preview

Leading Women-Run Companies Shaping the Future of Business

CNC, DAR, GD, FCEL and CC stocks show how women-led companies are redefining growth with discipline, agility and results.

news source

Zacks Investment Research • Aug 7, 2026

news preview

The Chemours Company (CC) Q2 2026 Earnings Call Transcript

The Chemours Company (CC) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Aug 6, 2026

news preview

Chemours: Close To A 'Perfect' Rotation, With A 'Buy' In Q2 2026 (Rating Upgrade)

Chemours is upgraded to 'BUY' with a $20 PT and $30 fair value, reflecting renewed upside after recent volatility. CC's recent rally was driven by sentiment, not fundamentals, but the company now shows improving liquidity, debt reduction, and solid EBITDA guidance. Risks remain from regulatory liabilities and elevated leverage, but CC's divestment plan and Opteon growth support a high-conviction turnaround thesis.

news source

Seeking Alpha • Aug 6, 2026

news preview

Why Chemours Plunged on Wednesday

Chemours disappointed investors with a slight revenue decline in Q2. However, there were some one-off factors that limited revenue in the second quarter.

news source

The Motley Fool • Aug 5, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Chemours Company (The)

Open an M1 investment account to buy and sell Chemours Company (The) commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CC on M1